Mabwell’s Mailishu (biosimilar, denosumab) Receives the NMPA’s Approval for the Treatment of Osteoporosis in China
- The NMPA has approved Mailishu, a denosumab biosimilar for the treatment of postmenopausal women with osteoporosis who are at high risk of fracture. Mailishu was developed by Mabwell’s wholly-owned subsidiary T-Mab
- Mailishu is the second approved biosimilar to denosumab, following the NMPA’s approval of Luye Pharma Group’s Boyobei (denosumab) in Nov 2022. Denosumab was marketed by Amgen under the trade names Prolia and Xgeva
- Additionally, Mailishu is designed to reduce the risk of vertebral, non-vertebral, and hip fractures within this patient segment
Ref: Mabwell | Image: Mabwell
Related News:- Disc Medicine Entered into an Exclusive License Agreement with Mabwell Therapeutics for Anti-TMPRSS6 Monoclonal Antibodies
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].